Although targeting TIM-3 in addition to PD-L1 and RT results in tumor growth delay and improved survival through reducing intra-tumoral Tregs frequency, the response is not durable since remaining infiltrating Tregs are highly proliferative and could expand, fostering tumor recurrence [34]. The gene discussed is HAVCR2; the disease is neoplasm.